Pharmacokinetics of high-dose methotrexate in infants treated for acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 52, Issue 5, 2009, Pages 596-601

  Lönnerholm, Gudmar ^a   Valsecchi, Maria Grazia ^b   De Lorenzo, Paola ^b   Schrappe, Martin ^c   Hovi, Liisa ^d   Campbell, Myriam ^e   Mann, Georg ^f   Janka Schaub, Gritta ^g   Li, Chi Kong ^h   Stary, Jan ⁱ   Hann, Ian ^j   Pieters, Rob ^k  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d UNIVERSITY OF HELSINKI   (Finland)

^e UNIVERSITY OF CHILE   (Chile)

^f ST ANNA CHILDREN S HOSPITAL   (Austria)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^k SOPHIA CHILDREN S HOSPITAL   (Netherlands)

more..

Author keywords

ALL; Infants; Methotrexate; Pharmacokinetics

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; FEMALE; HUMAN; INFANT; INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SEX DIFFERENCE; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; PATHOLOGY;

ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; METHOTREXATE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

EID: 63649141531     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21925     Document Type: Article

References (16)

1. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: Report on CCG 1953 from the Children's Oncology Group. Blood 2006;108:441 -451.
2. Pieters R, SchrappeM, DeLorenzoP, etal. Atreatmentprotocolfor infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): An observational study and a multicentre randomised trial. Lancet 2007;370:240-250.
3. Biondi A, Cimino G, Pieters R, et al. Biological and therapeutic aspects of infant leukemia. Blood 2000;96:24-33.
4. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemiaImplications for treatment of infants. Leukemia 1998;12:1344-1348.
5. Palle J, Frost BM, Forestier E, et al. Cellular drug sensitivity in MLL-rearranged childhood acute leukaemia is correlated to partner genes and cell lineage. Br J Haematol 2005;129:189-198.
6. Ramakers-van Woerden NL, Pieters R, Rots MG, etal. Infants with acute lymphoblastic leukemia: No evidence for high methotrexate resistance. Leukemia 2002;16:949-951.
7. Bleyer WA. The clinical pharmacology of methotrexate: New applications of an old drug. Cancer 1978;41:36-51.
8. Huffman DH, Wan SH, Azarnoff DL, et al. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973;14:572-579.
9. Siegel SE, Moran RG. Problems in the chemotherapy of cancer in the neonate. Am J Pediatr Hematol Oncol 1981;3:287-296.
10. McLeod HL, Relling MV, Crom WR, et al. Disposition of antineoplastic agents in the very young child. Br J Cancer Suppl 1992;18:S23 -S29.
11. Donelli MG, Zucchetti M, Robatto A, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995;24:154-159.
12. Thompson PA, Murry DJ, Rosner GL, et al. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2007;59:847-853.
13. Evans WE, Crom WR, Abromowitch M, et al. Clinical pharma- codynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. N Engl J Med 1986;314:471 -477.
14. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized chemotherapy for childhood acute lympho-blastic leukemia. N Engl J Med 1998;338:499-505.
15. Skarby TV, Anderson H, Heldrup J, et al. High leucovorin doses during high-dose methotrexate treatment may reduce the cure rate in childhood acute lymphoblastic leukemia. Leukemia 2006;20:1955 -1962.
16. Skarby T, Jonsson P, Hjorth L, et al. High-dose methotrexate: On the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother Pharmacol 2003;51:311-320.